F. Griesinger , X. Wang , P.S. Karia , M. Cooper , L. Servidio , E. Jedy-Agba , J.J. Nieva , D.B. Doroshow
{"title":"76P:一线(1L)奥西替尼单药治疗和后续治疗(tx)模式的长期生存结局:对美国表皮生长因子受体突变(EGFRm)晚期非小细胞肺癌(NSCLC)患者(pts)的真实世界(rw)研究的最终分析","authors":"F. Griesinger , X. Wang , P.S. Karia , M. Cooper , L. Servidio , E. Jedy-Agba , J.J. Nieva , D.B. Doroshow","doi":"10.1016/S1556-0864(25)00271-0","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":17515,"journal":{"name":"Journal of Thoracic Oncology","volume":"20 3","pages":"Pages S56-S57"},"PeriodicalIF":21.0000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"76P: Long-term survival outcomes with first-line (1L) osimertinib monotherapy and subsequent treatment (tx) patterns: Final analysis of a real-world (rw) study in US patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC)\",\"authors\":\"F. Griesinger , X. Wang , P.S. Karia , M. Cooper , L. Servidio , E. Jedy-Agba , J.J. Nieva , D.B. Doroshow\",\"doi\":\"10.1016/S1556-0864(25)00271-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":17515,\"journal\":{\"name\":\"Journal of Thoracic Oncology\",\"volume\":\"20 3\",\"pages\":\"Pages S56-S57\"},\"PeriodicalIF\":21.0000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Thoracic Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1556086425002710\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thoracic Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1556086425002710","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
76P: Long-term survival outcomes with first-line (1L) osimertinib monotherapy and subsequent treatment (tx) patterns: Final analysis of a real-world (rw) study in US patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC)
期刊介绍:
Journal of Thoracic Oncology (JTO), the official journal of the International Association for the Study of Lung Cancer,is the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis, and treatment of all thoracic malignancies.The readship includes epidemiologists, medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, radiologists, pathologists, nuclear medicine physicians, and research scientists with a special interest in thoracic oncology.